Bosutinib is a treatment that is already available for those patients who have not responded to previous treatments for CML. It is taken as a once-daily tablet and works by blocking certain signals in abnormal white blood cells and inhibiting cancer cell growth. Ongoing development of bosutinib is testing whether or not this treatment can be offered as a first-line therapy for CML patients.
Bosutinib (Bosulif) for Philadelphia positive chronic myeloid leukaemia – first line
Interventions:
Bosutinib (Bosulif; PF-05208763; bosutinib monohydrate)
Indications:
Chronic myeloid leukaemia (CML)
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2017